The Agence de Médecine Préventive, a not-for-profit organisation with headquarters at the Institut Pasteur in Paris and offices in Benin, Burkina Faso, Côte d'Ivoire and Senegal, has appointed Dr Kamel Senouci programme director for the SIVAC (Supporting Independent Immunization and Vaccine Advisory Committees) initiative. The programme aims to contribute to the development of national immunisation technical advisory groups in 12 countries – six in Africa and six in Asia. The project, funded by a $10 million grant from the Bill & Melinda Gates Foundation, will be conducted in partnership with the International Vaccine Institute and in co-operation with the World Health Organization.
French agency AMP makes new appointment
Listen to this article
The Agence de Médecine Préventive, a not-for-profit organisation with headquarters at the Institut Pasteur in Paris and offices in Benin, Burkina Faso, Côte d'Ivoire and Senegal, has appointed Dr Kamel Senouci programme director for the SIVAC (Supporting Independent Immunization and Vaccine Advisory Committees) initiative. The programme aims to contribute to the development of national immunisation technical advisory groups in 12 countries – six in Africa and six in Asia. The project, funded by a $10 million grant from the Bill & Melinda Gates Foundation, will be conducted in partnership with the International Vaccine Institute and in co-operation with the World Health Organization.
Keep up with the top pharma business news of the week. On the go.
More from Business
• By
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
• By
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains